These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants. El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558 [TBL] [Abstract][Full Text] [Related]
9. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. Stunnenberg BC; Raaphorst J; Groenewoud HM; Statland JM; Griggs RC; Woertman W; Stegeman DF; Timmermans J; Trivedi J; Matthews E; Saris CGJ; Schouwenberg BJ; Drost G; van Engelen BGM; van der Wilt GJ JAMA; 2018 Dec; 320(22):2344-2353. PubMed ID: 30535218 [TBL] [Abstract][Full Text] [Related]
10. N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita. Ke Q; Ye J; Tang S; Wang J; Luo B; Ji F; Zhang X; Yu Y; Cheng X; Li Y J Physiol; 2017 Nov; 595(22):6837-6850. PubMed ID: 28940424 [TBL] [Abstract][Full Text] [Related]
11. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. Vicart S; Franques J; Bouhour F; Magot A; Péréon Y; Sacconi S; Nadaj-Pakleza A; Behin A; Zahr N; Hézode M; Fournier E; Payan C; Lacomblez L; Fontaine B Neuromuscul Disord; 2021 Nov; 31(11):1124-1135. PubMed ID: 34702654 [TBL] [Abstract][Full Text] [Related]
13. Prolonged attacks of weakness with hypokalemia in SCN4A-related paramyotonia congenita. van Osch T; Stunnenberg BC; Sternberg D; Kerklaan BJ Muscle Nerve; 2018 Oct; 58(4):E27-E28. PubMed ID: 30028520 [No Abstract] [Full Text] [Related]
14. Successful long-term therapy with flecainide in a family with paramyotonia congenita. Terracciano C; Farina O; Esposito T; Lombardi L; Napolitano F; Blasiis P; Ciccone G; Todisco V; Tuccillo F; Bernardini S; Di Iorio G; Melone MAB; Sampaolo S J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1232-1234. PubMed ID: 29487168 [No Abstract] [Full Text] [Related]
15. Paramyotonia congenita due to a de novo mutation: a case report. Fukudome T; Izumoto H; Goto H; Matsuo H; Yoshimura T; Sakoda S; Shibuya N Muscle Nerve; 2003 Aug; 28(2):232-5. PubMed ID: 12872329 [TBL] [Abstract][Full Text] [Related]
19. In vivo assessment of muscle membrane properties in the sodium channel myotonias. Tan SV; Z'Graggen WJ; Hanna MG; Bostock H Muscle Nerve; 2018 Apr; 57(4):586-594. PubMed ID: 28877545 [TBL] [Abstract][Full Text] [Related]
20. Paramyotonia Congenita with Persistent Distal and Facial Muscle Weakness: A Case Report with Literature Review. Taminato T; Mori-Yoshimura M; Miki J; Sasaki R; Sato N; Oya Y; Nishino I; Takahashi Y J Neuromuscul Dis; 2020; 7(2):193-201. PubMed ID: 32083589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]